The Modified Appleby Procedure for Locally Advanced Pancreatic Body/Tail Cancer
Executive Summary
The modified Appleby procedure, technically known as distal pancreatectomy with celiac axis resection (DP-CAR), represents a specialized surgical intervention for locally advanced pancreatic adenocarcinoma of the body and tail. While approximately three-quarters of these tumors are deemed unresectable at presentation due to major vascular invasion, the modified Appleby procedure offers a potential path to negative margins (R0 resection) and improved survival for a highly selected group of patients.
The procedure is indicated specifically when a tumor involves the celiac axis or common hepatic artery but spares the superior mesenteric artery (SMA) and the head of the pancreas. Success relies heavily on the presence of collateral blood flow to the liver via the gastroduodenal artery (GDA) after the celiac axis is ligated. Although the procedure carries significant risks—including a 35–41% complication rate and potential ischemic gastropathy—recent data suggests that when combined with neoadjuvant therapy in high-volume centers, median survival can reach 20 to 30 months, significantly outperforming the 8.4 to 13 months typical of chemotherapy alone.
Historical Evolution and Overview
The Appleby procedure has transitioned from a gastric cancer treatment to a specialized tool for pancreatic surgery:
Origins (1953): Originally proposed by Appleby for locally advanced gastric cancer, involving an en bloc resection of the celiac axis, total gastrectomy, and distal pancreatectomy with splenectomy.
Modification (1976): Nimura et al. modified the procedure for pancreatic body/tail cancer by preserving the stomach (DP-CAR).
Modern Adoption: After falling out of favor due to high morbidity, the technique was endorsed again in the early 2000s. Advances in pancreatic surgery, improved selection criteria, and the advent of neoadjuvant therapy have led to more promising results.
Clinical Indications and Patient Selection
The modified Appleby procedure is an aggressive approach reserved for a small minority of patients. In some specialized series, it accounts for only 2% of all pancreatectomies.
Selection Criteria
Tumor Location: Adenocarcinoma limited to the body or tail of the pancreas.
Vascular Involvement: Involvement of the celiac axis or common hepatic artery.
Exclusions: The procedure is contraindicated if the tumor involves the SMA or the head of the pancreas, or if there is evidence of distant metastatic spread.
Functional Status: Patients must have high functional capacity and a demonstrated response to neoadjuvant therapy.
The Role of Neoadjuvant Therapy
Neoadjuvant therapy serves as a critical biological filter. By observing the tumor's response to chemotherapy before surgery, surgeons can eliminate patients with aggressive disease who would not benefit from a major resection. Approximately 20% of patients with locally advanced disease are considered surgical candidates following this strategy.
Diagnostic and Preoperative Assessment
Accurate imaging is the cornerstone of determining resectability and planning the vascular approach.
Preferred Modalities: Multi-phase pancreatic protocol CT or MRI is preferred for evaluating local invasion. PET/CT may be used to rule out metastatic disease in high-risk patients but is not mandatory.
Anatomical Focus: Specific attention must be paid to the celiac axis and the SMA.
Vascular Collateralization: The surgeon must confirm that the liver will receive adequate blood flow from the SMA through the inferior pancreaticoduodenal arteries and the GDA into the proper hepatic artery once the celiac axis is ligated.
Symptom Correlation: Presenting symptoms like gastric outlet obstruction or back pain may suggest local invasion of the stomach or celiac plexus/retroperitoneum, respectively.
Surgical Technique and Resectability Testing
The procedure is technically demanding and requires precise intraoperative verification of vascular integrity.
Determining Resectability
Diagnostic Laparoscopy: Recommended to rule out occult metastatic disease or carcinomatosis.
Extended Kocher Maneuver: Used to examine the pancreas in relation to the celiac axis, SMA, and GDA.
The Clamping Test: To ensure liver viability, the common hepatic artery is clamped. The surgeon then verifies pulsatile blood flow in the proper hepatic artery and GDA. If flow is poor, the common hepatic artery may require reconstruction to restore blood to the liver.
Key Technical Steps
Dissection: The pancreas and spleen are lifted from the retroperitoneum in an avascular plane. The distal splenic artery is divided early to allow the spleen to decompress.
Celiac Axis Division: The celiac axis is divided at its takeoff from the aorta. This is often the final step of the operation.
Perfusion Verification: Intraoperative fluorescein injection and fluorescent imaging are used to visualize the perfusion of the liver and stomach.
Vascular Reconstruction: If the liver or stomach appears ischemic, reconstruction may be performed using primary anastomosis (if mobile) or a saphenous vein graft.
Complications and Morbidity
The modified Appleby procedure is associated with higher morbidity than standard distal pancreatectomy.
To minimize risks, surgeons may assess gastric perfusion by checking mean arterial pressure (MAP) from the hepatic and left gastric stumps. A drop in MAP of >25% is used by some as a criterion for arterial reconstruction.
Clinical Outcomes and Survival Data
Recent institutional series show that while the procedure is aggressive, it is safe when performed in tertiary multidisciplinary centers on properly selected patients.
Survival Statistics
With DP-CAR and Neoadjuvant Therapy: Median survival ranges between 20 and 30 months.
Chemotherapy Alone: Median survival for unresectable locally advanced disease is 8.4 to 13 months.
FOLFIRINOX Specifics: Median survival for metastatic disease treated with FOLFIRINOX is approximately 11 months.
Comparative Series (Table 19.1 Summary)
Conclusions
Arterial resection via the modified Appleby procedure should be reserved for a highly specific patient population: those with locally advanced pancreatic body/tail cancer where vascular involvement is strictly limited to the celiac axis or common hepatic artery. The integration of neoadjuvant chemotherapy is essential for selecting patients who will truly benefit from such an aggressive surgical intervention. When R0 resection is achieved, long-term survival outcomes for these patients can mirror those of patients with primarily resectable pancreatic cancer.
